Abstract: Implantable or insertable medical devices are described, which include one or more polymeric regions and one or more therapeutic agents. The polymeric regions, which regulate the release of one or more therapeutic agent from the medical device, contain copolymer molecules, each of which includes one or more soft segments and one or more uniform hard segments (e.g., polyamide segments that do not vary in length from molecule to molecule, among others).

Abstract: A co-polyester which includes the reaction product of a polycondensation polyester and epsilon-caprolactone, wherein the polycondensation polyester comprises the reaction product of diglycolic acid and/or a derivative thereof and a diol. The co-polyester is injectable and absorbable into animal, such as human, tissue and can be used for facial cosmetic or reconstructive surgery of soft tissue. Another embodiment is directed to a method for preventing adhesion using a co-polyester comprising the reaction product of a polycondensation polyester and epsilon-caprolactone, wherein the polycondensation polyester comprises the reaction product of diglycolic acid and/or a derivative thereof and a diol, and the co-polyester comprises about 40 to 50% by weight of the polycondensation polyester based on the total weight of the co-polyester.

Abstract: Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.

Abstract: A contact lens product, a method and system for forming the contact lens product, and a method of using the contact lens product. The contact lens product includes a soft disposable contact lens loaded with a drug and the carriers which carry the drug. The lens has a mechanical and optical structure formed by the core polymer included within the lens. The contact lens product is configured to have the drug released from its carrier continuously into an eye of a mammal while the contact lens product is adhered to the eye of the mammal during a continuous period of time, the drug being configured to treat or prevent at least one adverse condition of the eye of the mammal during the continuous period of time. The mammal may be a human being or a veterinary animal.

Abstract: The present invention concerns a method of enhancing milk production by a ruminant that includes providing a feed that contains sorbitol and at least one additional feed component, and orally feeding the feed to the ruminant, the ruminant ingesting about 100 grams, or less, of sorbitol per day.

Abstract: The present invention provides compositions for and methods of delivering a therapeutically-effective dose of a malodorous, sulfide or disulfide group-containing compound, for example glutathione (reduced) and/or glutathione disulfide, in a vehicle that is effective to reduce the unpleasant odor and/or taste of the compound. The invention further provides methods for reducing the amount of oxidation occurring when sulfide group-containing compounds, such as glutathione, are incorporated into sugar and or sugar-free hard candies without subjecting the glutathione to thermal and or moisture degradation where degradation is expressed as oxidation. The invention further provides vehicle compositions including the protected sulfide group-containing compounds and their use as medicaments. The sulfide group-containing compounds are protected from degradation by their dispersion into fats, oils, and/or fractionated or partially hydrogenated oils prior to their blending into the vehicle.

Abstract: A transdermal analgesic system having reduced potential for abuse, wherein the system provides for the controlled release of the antagonist at a rate sufficient to provide an abuse limiting release rate ratio of the antagonist to the analgesic when the dosage form is subject to abuse is disclosed.

Abstract: The invention concerns a transdermal delivery system for controlled dispensing of an active substance to and through a porous surface. A certain amount of fluid comprising at least one active substance and at least one solvent is dispensed into an administration reservoir. In the administration reservoir the at least one solvent is separated from the administration reservoir by a solvent recovery means such that the active substance achieves a certain level on an interface device which is permeable for the one active substance. Thereby the active substance is absorbable via diffusion from the interface device by a porous surface to be treated.

Abstract: A dermal or transdermal therapeutic system comprising a reservoir that contains at least one active substance, an active substance-permeable membrane which delimits the active-substance reservoir, and a closing layer. The closing layer is impermeable to the active substance at a temperature lying below the skin temperature while being permeable at skin temperature and above.

Abstract: A sustained release dosage form comprising Quetiapine or a pharmaceutically acceptable salt, polymorphs, solvates, hydrates thereof and one or more non-gellable release controlling polymer and one or more pharmaceutically acceptable excipient(s). A sustained release dosage form comprising first granulation comprising Quetiapine or its pharmaceutically acceptable salts, polymorphs, solvates, hydrates thereof and one or more release controlling material; and second granulation comprising one or more release controlling material which is the same or different than the one or more release controlling material of the first granulation and optionally quetiapine or its pharmaceutically acceptable salts, polymorphs, solvates, hydrates thereof. A method of preparing the sustained release dosage form by first and second granulation followed by milling; blending the said milled granules after second granulation with lubricant followed by compression to form a sustained release dosage form.

Abstract: A multi-component pharmaceutical dosage form comprising a plurality of drug substance—containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form by a weld between parts of the assembled dosage form.

Abstract: The present invention is directed to processes of making flowable hemostatic compositions and devices that include the flowable hemostatic composition disposed therein, where a volume of a biocompatible liquid, a volume of a biocompatible gas, and an amount of solid particles of a biocompatible polymer are mixed together to form a substantially homogenous composition including a discontinuous gas phase and the solid particles substantially homogenously dispersed throughout a continuous liquid phase to form a flowable hemostatic composition, and the composition then transferred into a device suitable for applying the flowable hemostatic composition to a site of a body requiring hemostasis under conditions effective to maintain the substantially homogeneous dispersion of the gas phase and the solid particles throughout the liquid phase, wherein said transfer of said substantially homogenous hemostatic composition is conducted at an angle.

Abstract: A nonaqueous, single-phase vehicle that is capable of suspending an active agent. The nonaqueous, single-phase vehicle includes at least one solvent and at least one polymer and is formulated to exhibit phase separation upon contact with an aqueous environment. The at least one solvent may be selected from the group consisting of benzyl benzoate, decanol, ethyl hexyl lactate, and mixtures thereof and the at least one polymer may be selected from the group consisting of a polyester, pyrrolidone, ester of an unsaturated alcohol, ether of an unsaturated alcohol, polyoxyethylenepolyoxypropylene block copolymer, and mixtures thereof. In one embodiment, the at least one solvent is benzyl benzoate and the at least one polymer is polyvinylpyrrolidone. A stable, nonaqueous suspension formulation that includes the nonaqueous, single-phase vehicle and an active agent, and a method of forming the same, are also disclosed.

Abstract: A biological adhesive formulation comprising dextrin, at least one adhesiveness modifier agent, and at least one antibiotic is suitable for promoting healing of tissue in a patient, for example, to prevent anastomosis of a surgical wound in the digestive system of a patient, and for affixing prosthesis during a hernia operation in a patient and occluding a fistula within a patient.

Abstract: An adsorbent for an oral administration, comprising a spherical activated carbon wherein an average particle diameter is 50 to 200 ?m, a specific surface area determined by a BET method is 700 m2/g or more, and a bulk density is less than 0.54 g/mL is disclosed. The adsorbent for an oral administration has a high adsorbability, and is capable of adsorbing a large amount of toxins during a retention period in an intestine, and of remarkably increasing an adsorption amount of compounds having a large molecular weight.

Abstract: The disclosure provide hollow nanospheres and methods of making and using the same. The methods and compositions of the disclosure are useful for drug delivery and gene transfer.

Abstract: The present invention is related to a formulation based on micronized natural calcite mineral consisting of: A. mineral part which is characterized: (i) by the particle size with diameter smaller than 5 ?m, where the distribution of particle size is such that minimum of 10% of particles are with diameter under 900 nm, with total surface of particles greater than 3.2 m2/g, and with total porous volume greater than 0.012 cm3/g, and by composition: (ii) CaCO3, MgCO3, FeCO3, MnCO3, ZnCO3 and SiO2 in mixtures where CaCO3 is presented in amount from 10% to 99% of mineral part; and B. adjuvant selected from the group consisting of: wetting agent, drift-control agent at application by spraying, humic acid salt, amino-acids salts, complex of plant micro-nutrients, vitamin, plant hormone, nitrogen fertilizer, potassium salt, borate salt, molybdate salt, plant extract, chlorophyll, yeast extract, or mixture of these substances; where A. and B. form an aqueous suspension wherein percentage of A. and B.

Abstract: Swellable particles for delivery of a drug or other working agent to the pulmonary system are provided. The swellable particles include a dehydrated (dry) aerodynamic particle diameter of 5 ?m or less to enable delivery to the respiratory tract, such as for example to the tracheo-bronchial airways of the upper respiratory tract and/or to the alveolic regions of the deep lung, and a hydrated particle diameter that is greater than 6 ?m volume mean diameter to retard or prevent their phagocytosis by the macrophages present in airways of the respiratory tract.

Abstract: A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.

Abstract: The present inventors discovered that microfiltration retentates of whey, and products obtained by treating whey using centrifugation and/or ammonium sulfate precipitation, have the activity of inhibiting rotavirus infection. In one embodiment, the present invention provides a method of preventing rotavirus infection, comprising administering to a subject a composition that comprises a whey cream serum obtained by treating whey by centrifugation, or a dehydrated product thereof, wherein the antiviral activity of said composition is retained after heat treatment.

Abstract: Bee venom may be administered in a standardized formulation with or without relatively small amounts of anesthetic. In particular, the results of the combination of venom and anesthetic dramatically decreased pain and discomfort for patients undergoing apitherapy.

Abstract: Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF ? signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.

Abstract: Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.

Abstract: Disclosed is a topical skin care composition and corresponding methods for their use comprising Arctium lappa (Burdock) root extract, Epilobium angustifolium (Canadian Willowherb) extract, or Cystoseira amentacea/Caespitosa Brachycarpa extract, or any combination thereof.

Abstract: The present invention discloses a sulfated derivative of polysaccharide extracted from gastrodia elata BL., the preparation method thereof and the use thereof in preparing antineoplastic medicaments, wherein, the gastrodia elata polysaccharide has the following structure: wherein, x and y are each an integer, and x+y=16, “n” is and integer, and the mean molecular weight of the polysaccharide from gastrodia elata is estimated as 2.8×105, the specific rotation of the polysaccharide is +95° in a 0.5 mg/mL aqueous solution thereof; the sulfated position is mainly at 6-hydroxy of the gastrodia elata polysaccharide, with mean molecular weight of 6.5×104 and a specific rotation of +150.0° in a 0.5 mg/mL aqueous solution thereof.

Abstract: A formulation for trichological treatment of a patient including, in a dosage in the range of 3 g to 8 g: phytosterols in the range of 200 mg to 2500 mg; the quantitative equivalent of Polygonum multiflorum root 4:1 in 70% EW in the range of 600 mg to 2600 mg; methylsulfonylmethane in the range of 500 mg to 2000 mg; and bovine colostrum in the range of 500 m to 2000 m.

Abstract: The present invention relates to a method for treating a disorder chosen from ocular Demodex, Demodex-induced blepharitis, rosacea, acne, and meibomian gland dysfunction in a patient in need thereof, comprising administering to the patient a composition comprising a therapeutically effective amount of a substance chosen from at least one of an isoprenoidal essential oil such as Tea Tree Oil; Terpinen-4-ol; Carvone; alpha-Terpineol; Cardinene; d-Carvone; l-Carvone; gamma-Terpinene; alpha-Terpinene; 1,8-Cineole; alpha-Terpineol; para-Cimene; alpha-Pinene; Limonene; (R)-(+)-Limonene; alpha-Thugene; Eucalyptol; (+)-Ledene; Cuminic Aldehyde; and Myrcene; the administration comprising contacting or scrubbing an affected area of skin or hair, or eyelid margin and lashes of the patient with the composition; also disclosed are a method for treating mange and mite infestations on a mammalian animal; and kits for in-office and at home treatments of the disorders.

Abstract: A alcohol metabolizing assisting supplement includes a mixture which includes humic and fulvic acids, L-Cysteine, L-Glutamine, thiamine mononitrate, and vitamins. The mixture is ingested after the consumption of alcohol to assist the body in quickly metabolizing the alcohol and to resist the negative effects of metabolizing alcohol.

Abstract: A alcohol metabolizing assisting supplement includes a mixture which includes humic and fulvic acids, L-Cysteine, L-Glutamine, thiamine mononitrate, and vitamins. The mixture is ingested after the consumption of alcohol to assist the body in quickly metabolizing the alcohol and to resist the negative effects of metabolizing alcohol.

Abstract: A composition comprising various vitamins to make a multi-vitamin. The vitamins identified in multi-vitamin include vitamin B-1, vitamin B-2, niacinamide, vitamin B-6, vitamin B-12, pantothenic acid, folic acid, beta carotene, iron, biotin, choline, vitamin A, vitamin E and vitamin C. The multi-vitamin soothe pain, depression, weakness and insomnia and works best with variety of food and less dairy products. Lead combined with calcium effects are severe than lead effects only; it elevates blood pressure, cholesterol, glucose, weight and cause frequent infections; bigger than normal dose of antibiotics need in infections; and variation in quantities of few vitamins are needed to soothe the symptoms.

Abstract: The invention relates to a method of producing a chocolate drink containing at least 2% cacao. The inventive method includes a step involving inserting a capsule containing a concentrate of the chocolate drink into a coffee machine of the type which allows the pressure percolation of a dose of coffee. The invention also relates to the concentrate which is used to prepare the chocolate drink and to the capsules containing said concentrate.

Abstract: Disclosed are nutritional compositions and methods for preparing the compositions, comprising fat, protein, and carbohydrate, including a combination of curcumin, demethoxycurcumin, and bisdemethoxycurcumin, which combination is solubilized in a polar oil having an HLB value of from about 0.7 to about 14 wherein the weight ratio of the bisdemethoxycurcumin to the curcumin is from about 1:1 to about 1:7 and the weight ratio of the bisdemethoxycurcumin to the demethoxycurcumin is from about 1:1 to about 1:2.5. The composition provides a selected ratio of curcuminoids having improved biological activity, bioavailability, and reduced color impact.

Abstract: By containing non-polymer catechins in high concentration, the physiological effects of the catechins are manifested, minerals indispensable to the living body are fortified, and the storage stability of a beverage is improved. A packaged beverage containing: (A) from 0.05 to 0.5% by mass of non-polymer catechins; (B) from 0.0012 to 0.12% by mass of calcium; (C) from 0.00012 to 0.006% by mass of magnesium; (D) from 0.000048 to 0.0024% by mass of zinc; (E) from 0.00004 to 0.002% by mass of iron; and (F) from 0.01 to 20% by mass of a sweetener, wherein a content mass ratio [(B)/(A)] of the calcium (B) to the non-polymer catechins (A) is from 0.001 to 1.0; (J) a percentage of gallate bodies in the non-polymer catechins is from 5 to 55% by mass; and pH is from 2.5 to 5.1.

Abstract: The present invention relates to a method for preparing flavored teas by using wood, and flavored teas prepared thereby. More specifically, the present invention relates to a preparation method of flavored teas with excellent palatability and flavors in which the method uses natural wood along with the appropriate flavoring time and temperature settings, and flavored teas prepared thereby.

Abstract: Citrus juice beverage products and their method of production are formulated to reduce the sugar content of the beverage while the beverage products have sensory, taste, mouth feel and texture characteristics that mimic those of whole citrus juice. Orange juice beverage products are especially preferred. The beverage products have a relatively low Brix, on the order of between about 7 and about 8 Brix. Also included in the beverage products is a sweetener which does not add a significant caloric load to the beverage product. A sinking pulp added to the beverage product in an amount to achieve texture and other sensory characteristics of a whole juice.

Abstract: Provided is a crystallization accelerator capable of accelerating fat crystallization a short time during a production step of a product of margarine, shortening, chocolate, or hard butter to be used for confectionery production or bread production. A phenomenon that sorbitan fatty acid ester having an esterification ratio of from 28 to 60% and a sorbitol-type content of from 20 to 40% exhibits a remarkable effect on acceleration of fat crystallization in a short time was found, and thus, the invention was completed.

Abstract: Improved doughs containing dehydrated potato products, food products made from said doughs, and the methods for making the same are disclosed. Although the improved doughs contain non-ideal dehydrated potato products, processing efficiency and finished product quality are comparable to that of finished products made with doughs containing dehydrated potato products having from 40% to 60% broken cells and from 16% to 27% free amylose.

Abstract: The invention discloses a novel iodizing agent containing latent elemental iodine and preparation of iodized salt therefrom. The iodizing agent comprises a mixture of iodide and iodate in solution form in 5:1 molar ratio. The said iodizing agent may be prepared cost-effectively through the reaction of pure iodine crystals with a suitable alkali. Iodized salt prepared therefrom is stable in the pH range of 7.0-8.0 whereas it releases the latent elemental iodine under acidic conditions such as that which prevails in the stomach.

Abstract: A droplet discharge amount measuring method for measuring the amount of droplets of a functional solution discharged from a droplet discharge apparatus, the functional solution containing a solid component and a solvent, includes discharging droplets of the functional solution from the droplet discharge apparatus onto a test surface, drying for allowing the solvent on the test surface to evaporate from the droplets so that solid dots be left and measuring the volume of the solid dots using an imaging technique, wherein in drying, the droplets are condensed as the solvent evaporates therefrom, and thus the resulting solid dots have smaller areas than the parent droplets upon landing on the test surface.

Abstract: A method for preparing a multilayer of nanocrystals. The method includes the steps of (i) coating nanocrystals surface-coordinated by a photosensitive compound, or a mixed solution of a photosensitive compound and nanocrystals surface-coordinated by a material miscible with the photosensitive compound, on a substrate, drying the coated substrate, and exposing the dried substrate to UV light to form a first monolayer of nanocrystals, and (ii) repeating the procedure of step (i) to form one or more monolayers of nanocrystals on the first monolayer of nanocrystals. Further, an organic-inorganic hybrid electroluminescence device using a multilayer of nanocrystals prepared by the method as a luminescent layer.

Abstract: There is provided a method of making a heat treated (HT) coated article to be used in shower door applications, window applications, or any other suitable applications where transparent coated articles are desired. For example, certain embodiments of this invention relate to a method of making a coated article including a step of heat treating a glass substrate coated with at least a layer of or including diamond-like carbon (DLC) and an overlying protective film thereon. In certain example embodiments, the protective film may be of or include both (a) an oxygen blocking or barrier layer, and (b) a release layer. Following and/or during heat treatment (e.g., thermal tempering, or the like) the protective film may be removed. Other embodiments of this invention relate to the pre-HT coated article, or the post-HT coated article.

Abstract: Certain example embodiments of this invention relate to a method of forming a coating on a glass substrate using combustion deposition. A glass substrate having at least one surface to be coated is provided. A reagent is selected. A precursor to be combusted with the reagent is introduced. Using at least one infrared burner, at least a portion of the reagent and the precursor are combusted to form a combusted material, with the combusted material including non-vaporized material. The glass substrate is provided in an area so that the glass substrate is heated sufficiently to allow the combusted material to form the coating, directly or indirectly, on the glass substrate. The coating may be substantially uniform. In certain example embodiments, a silicon oxide coating may be deposited, which increases visible transmission of the glass substrate by at least about 1.7%.

Abstract: Methods of forming fasteners are disclosed. One method comprises dispersing polymer particles into a contact release surface, transforming the polymer particles into an at least semiliquid state of a suitable viscosity for a time sufficient to transform into preform projections having contact edges, contacting and fixing a front surface of the base with the terminal ends of at least some of the preform projections, removing the base, thereby separating the preform projections, from the release surface, and forming engaging projections projecting from the front surface of the base.

Abstract: The invention relates to a process for the non-covalent coating of a support by a hybrid organic/inorganic film, characterized in that it comprises the steps of: —depositing a conjugated organic polymer comprising organic groups of X type onto the support; depositing nanoparticles comprising one or more organic groups of Y type onto the support, and in that the groups of X and Y types are capable of developing hydrogen-type bonds between themselves. Typically, the deposition steps are repeated, generally alternately, until the desired thickness for the film is obtained. The deposition may be carried out on the whole of the support or on one part of the latter only.

Abstract: A combinatorial processing chamber and method are provided. In the method a fluid volume flows over a surface of a substrate with differing portions of the fluid volume having different constituent components to concurrently expose segregated regions of the substrate to a mixture of the constituent components that differ from constituent components to which adjacent regions are exposed. Differently processed segregated regions are generated through the multiple flowings.

Abstract: A diruthenium complex such as tetra(?-formato)diruthenium(II,II) or tetra(?-formato)(dehydrate)diruthenium(II,II), a material for chemical vapor deposition which comprises the complex, and a method of forming a ruthenium film from the material by chemical vapor deposition.

Abstract: A surface treating method for making a housing have a metallic glass main body comprising: coating a primer on the metallic glass main body to form a bottom layer; forming a plating layer on the bottom layer; coating an adhesive on the plating layer to form an adhesive layer; and coating a lacquer on the adhesive layer to form an outer layer.

Abstract: The invention relates to a composition which, when mixed with a polymer composition, allows for the formation of a continuous and cohesive film. The film is characterized in that it provides water, grease and oil resistance, provides a water vapor barrier and can be used as wax replacement treatment and a top coat for flexible packaging, but also on other substrates. This film is formed at a very fast set speed without the need of thermal energy. The composition contains i) a salt of one or more of myristic, palmitic and stearic acid; and preferably also ii) a C9-C18 fatty acid complex of a metal ion, said metal ion having an oxidation state of at least 3. The invention also provides processes and coated substrates.

Abstract: A method for forming a metallic pattern, which is provided with a printing process to print a pattern portion on a substrate by means of an inkjet method utilizing ink containing a precursor of a nonelectric plating catalyst and a plating process to form a metallic pattern by nonelectric plating on said pattern portion, wherein the surface of said substrate is constituted of ink non-absorptive resin and has been subjected to a plasma treatment, and said ink has a pH value at 25° C. of not less than 9.0.

Abstract: According to one embodiment of the present invention, a method for preparing a brazed surface to receive a coating is disclosed. The method includes providing a brazed surface having a flux layer including a conversion coating and a powder component; and applying an aqueous solution containing a flux-removing agent to the surface to at least partially remove the powder component of the flux layer to obtain a treated brazed surface that is suitable for receiving a subsequent coating layer.